SCHEMBL5322260

SCHEMBL5322260

NC(CCCc1cccc2ccccc12)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.51
SLC1A2 P43004 1/20 0.51
SLC1A1 P43005 1/20 0.51
TDP1 Q9NUW8 2/20 0.50
MTNR1A P48039 1/20 0.50
MCL1 Q07820 2/20 0.48
KIF11 P52732 1/20 0.48
CTNNB1 P35222 1/20 0.47
METAP2 P50579 1/20 0.46
GRIK1 P39086 1/20 0.46
OPRK1 P41145 1/20 0.45
KMT2A Q03164 2/20 0.45
COPS5 Q92905 1/20 0.45
NOS1 P29475 1/20 0.45
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5325351 0.95 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1TDP1MTNR1A
SCHEMBL5324039 0.91 SLC1A3 (0.54) SLC1A3SLC1A2SLC1A1TDP1MTNR1A
SCHEMBL27254773 0.84 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1TDP1MTNR1A
SCHEMBL5322217 0.82 TDP1 (0.51) SLC1A3SLC1A2SLC1A1TDP1MTNR1A
Oxalic Acid SCHEMBL9517848 0.81 KMT2A (0.48) SLC1A3SLC1A2SLC1A1TDP1MTNR1A
Oxalic Acid SCHEMBL9517855 0.81 KMT2A (0.48) SLC1A3SLC1A2SLC1A1TDP1MTNR1A
SCHEMBL29397858 0.81 CTNNB1 (0.59) SLC1A3SLC1A2SLC1A1TDP1KIF11
SCHEMBL29482763 0.81 CTNNB1 (0.59) SLC1A3SLC1A2SLC1A1TDP1KIF11
SCHEMBL29397866 0.81 CTNNB1 (0.59) SLC1A3SLC1A2SLC1A1TDP1KIF11
SCHEMBL93515 0.81 CTNNB1 (0.59) SLC1A3SLC1A2SLC1A1TDP1KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 SLC1A3 4472/4885SLC1A2 4787/4885SLC1A1 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.